607370-99-0

Basic information

• Product Name: 4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine
• Synonyms: 4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine;4-(7-BroMo-1-ethyl-1H-iMidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-aMine
• CAS NO: 607370-99-0
• Molecular Formula: C₁₀H₉BrN₆O
• Molecular Weight: 309.12206
• Mol File: 607370-99-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine(607370-99-0)
• EPA Substance Registry System: 4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine(607370-99-0)

Safety Data

• Hazardous Substances Data: 607370-99-0(Hazardous Substances Data)

Usage

Uses

Used in Medicinal Chemistry:
4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine is used as a key intermediate in the synthesis of pharmaceuticals for its potential to interact with specific biological targets. Its unique structure allows for the development of drugs that can modulate cellular processes and pathways, offering new therapeutic options for various diseases and conditions.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine serves as a building block for the creation of novel drug candidates. Its incorporation into drug molecules can enhance their efficacy, selectivity, and pharmacokinetic properties, leading to improved treatments and better patient outcomes.
Used in Research and Development of New Materials:
4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine is utilized in the research and development of innovative materials due to its distinctive chemical and physical properties. Its potential applications in this field include the design of new materials with specific functionalities, such as sensors, catalysts, or advanced materials for various industrial applications.
Used in Organic Synthesis:
In the realm of organic synthesis, 4-(7-Bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-ylamine is employed as a versatile reactant for the creation of new chemical entities with tailored properties. Its reactivity and structural features make it a valuable component in the synthesis of complex organic molecules, which can find applications in various sectors, such as agrochemicals, dyes, or advanced materials.

Upstream product

• 607371-03-9 5-bromo-N4-ethylpyridine-3,4-diamine 
• 607371-01-7 ethyl-(3-bromo-5-nitropyridin-4-yl)amine 
• 562825-95-0 ethyl-(3-nitropyridin-4-yl)amine 
• 842143-97-9 (7-bromo-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile 

Downstream Products

• 607372-25-8 4-(1-ethyl-7-{[4-(methyloxy)phenyl]thio}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine 
• 850850-86-1 N-(4-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-7-yl]thio}phenyl)acetamide 
• 850850-62-3 4-(1-ethyl-7-{[4-(methyloxy)phenyl]sulfinyl}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine 

Relevant articles and documents

(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Further optimisation as highly potent and selective MSK-1-inhibitors

The novel imidazo[4,5-c]pyridine 1,2,5-oxadiazol-3-yl template affords an excellent start point for identification of inhibitors of a number of protein kinases. Here we report on its optimisation for mitogen and stress-activated protein kinase-1 (MSK-1) inhibitory activity, and selectivity over other kinases.

MICROBIOCIDAL 4-(IMIDAZO[4,5-C]PYRIDIN-2-YL)-1,2,5-OXADIAZOL-3- AMINE COMPOUNDS HAVING AN OXIME GROUP IN POSITION 7

The present invention provides compounds of formula (I) wherein Y1, Y2, Υ3, Υ4 and Υ5 are as defined in the claims. The invention further relates to compositions which comprise these compounds and to

Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3- piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

Overexpression of AKT has an antiapoptotic effect in many cell types, and expression of dominant negative AKT blocks the ability of a variety of growth factors to promote survival. Therefore, inhibitors of AKT kinase activity might be useful as monotherapy for the treatment of tumors with activated AKT. Herein, we describe our lead optimization studies culminating in the discovery of compound 3g (GSK690693). Compound 3g is a novel ATP competitive, pan-AKT kinase inhibitor with IC50 values of 2, 13, and 9 nM against AKT1, 2, and 3, respectively. An X-ray cocrystal structure was solved with 3g and the kinase domain of AKT2, confirming that 3g bound in the ATP binding pocket. Compound 3g potently inhibits intracellular AKT activity as measured by the inhibition of the phosphorylation levels of GSK3β. Intraperitoneal administration of 3g in immunocompromised mice results in the inhibition of GSK3β phosphorylation and tumor growth in human breast carcinoma (BT474) xenografts.

INHIBITORS OF Akt ACTIVITY

Invented are novel 1 H-imidazo[4,5-c]pyridin-2-yI compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer.

PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS

Novel inhibitors of Rho-kinases are disclosed.